Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
29.55
+3.03 (11.43%)
At close: Mar 12, 2025, 4:00 PM
30.05
+0.50 (1.68%)
After-hours: Mar 12, 2025, 7:58 PM EST
Viking Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Viking Therapeutics stock have an average target of 96.31, with a low estimate of 38 and a high estimate of 138. The average target predicts an increase of 225.92% from the current stock price of 29.55.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Viking Therapeutics stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 8 | 8 | 7 |
| Buy | 3 | 3 | 4 | 4 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 12 | 12 | 14 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $102 | Strong Buy | Reiterates | $102 | +245.18% | Mar 11, 2025 |
| Scotiabank | Scotiabank | Buy Initiates $102 | Buy | Initiates | $102 | +245.18% | Feb 13, 2025 |
| Citigroup | Citigroup | Hold Initiates $38 | Hold | Initiates | $38 | +28.60% | Feb 7, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $120 → $70 | Strong Buy | Maintains | $120 → $70 | +136.89% | Feb 7, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Reiterates $109 → $96 | Strong Buy | Reiterates | $109 → $96 | +224.87% | Feb 7, 2025 |
Financial Forecast
Revenue This Year
1.59M
Revenue Next Year
7.02M
from 1.59M
Increased by 340.28%
EPS This Year
-1.63
from -1.01
EPS Next Year
-2.21
from -1.63
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.3M | 97.9M | 149.4M | ||
| Avg | 1.6M | 7.0M | 21.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 6,039.3% | 2,028.4% | ||
| Avg | - | 340.3% | 211.2% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.03 | -1.61 | -0.87 | ||
| Avg | -1.63 | -2.21 | -2.55 | ||
| Low | -2.12 | -3.04 | -3.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.